Celldex touts success of early-stage therapeutic cancer vaccine study; Cyprotex teams with Pfizer on predictive toxicology;

 @FierceBiotech: Alzheimer's investigators see fresh sign of solanezumab success in $LLY study. More | Follow @FierceBiotech

 @JohnCFierce: Biotech companies out there. You have any bad news to report? Do it now. Take advantage of the perfect storm to confess your sins quietly. | Follow @JohnCFierce

 @RyanMFierce: Focusing on hoped-for launch of tivozanib, $AVEO is axing 45 jobs or 17% of workers, eliminating 30 openings. More | Follow @RyanMFierce

> Celldex Therapeutics has claimed a first among therapeutic cancer vaccine developers, saying its CDX-1401 triggered a strong immune response in solid tumors in a Phase I study. Investigators say that's the first time an "off-the-shelf" vaccine registered such a strong response. Release

> Shares of the U.K.'s Cyprotex got a boost today from the news that it will collaborate with Pfizer ($PFE) on a research deal that covers an 18-month time span split into two stages. They'll be working on predictive toxicology. Story

> Titan Pharmaceuticals has filed an NDA for Probuphine. Story

> AET BioTech and Swiss biotech BioXpress Therapeutics have struck a deal to collaborate on a biosimilar version of adalimumab. Story

Pharma News

@FiercePharma: Korean pharma stocks are riding an updraft of M&A speculation. Keunwha, Hondok way up ... anyone shopping? More | Follow @FiercePharma

> Boehringer Ingelheim bets bigger on respiratory drugs. Story

> Bayer adds vitamin maker Schiff to buyout tally with $1.2B deal. News

> Patheon nabs Mexican beachhead with $255M Banner buyout. Report

Medical Device News

 @FierceMedDev: Ariste Medical raised $1.275M in seed money to advance development of a drug-coated vascular graft. More | Follow @FierceMedDev

 @MarkHFierce: CryoLife celebrates 13% revenue jump in Q3. More | Follow @MarkHFierce

 @DamianFierce: Orthofix pays $32M to settle allegations it gave kickbacks--including parties with strippers & prostitutes--to docs. More | Follow @DamianFierce

> Report: Global neuromodulation device market ripe for double-digit growth. Item

> Medtronic looks to unseat Edwards with heart valve. Report

Pharma Manufacturing News

> Boehringer again doubling capacity at inhaler plant. Report

> Patheon will pick up four plants with Banner buyout. News

> Congressional report calls for FDA to regulate large compounders. Article

> Drugmakers close plants ahead in face of Hurricane Sandy. Item

Biotech Research News

> Wisconsin company to provide stem cells for NIH research. Story

> Roche drug, microRNA treatment conquered head and neck cancer cells. News

> Baker's yeast yields possible Lou Gehrig's disease drug target. Article

> Duke team builds viable cartilage from induced pluripotent stem cells. Report

And Finally… Exercise doesn't just make you physically fit. A new study says it can also clearly make you smarter. Release

 

Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.